Evidence map›Paper›PMID 41787366›Full record

ArticleBMC psychiatry2026

Unexpected resolution of clozapine-induced obsessive-compulsive symptoms with cariprazine augmentation: a case report.

Ismail Rammouz, Omar El Oumary, Saliha Hamri, Khadija Akebour, Khalid Mouhadi, Jalal Doufik, Said Boujraf

Abstract readCase Reports
In one paragraph

Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ismail RammouzClinical Neurosciences Innovation and Ethic (NICE), Laboratory REGNE, Faculty of Medicine, Ibn Zohr University, Agadir, Morocco.
Omar El OumaryClinical Neurosciences Innovation and Ethic (NICE), Laboratory REGNE, Faculty of Medicine, Ibn Zohr University, Agadir, Morocco.
Saliha HamriClinical Neurosciences Innovation and Ethic (NICE), Laboratory REGNE, Faculty of Medicine, Ibn Zohr University, Agadir, Morocco.
Khadija AkebourClinical Neurosciences Innovation and Ethic (NICE), Laboratory REGNE, Faculty of Medicine, Ibn Zohr University, Agadir, Morocco.
Khalid MouhadiClinical Neurosciences Innovation and Ethic (NICE), Laboratory REGNE, Faculty of Medicine, Ibn Zohr University, Agadir, Morocco.
Jalal DoufikClinical Neurosciences Innovation and Ethic (NICE), Laboratory REGNE, Faculty of Medicine, Ibn Zohr University, Agadir, Morocco.
Said BoujrafClinical Neurosciences Laboratory, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco. sboujraf@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe management of obsessive–compulsive symptoms (OCS) in patients with schizophrenia is challenging, as many antipsychotics can induce OCS. Increasing evidence supports the use of partial agonists in managing these cases. This case report describes a patient with treatment-resistant schizophrenia and clozapine-induced obsessive–compulsive symptoms who underwent multiple antipsychotic regimens without significant improvement. THE PATIENT’S MAIN CONCERNS AND IMPORTANT CLINICAL

findingsThe patient's symptoms progressed gradually, and their condition was managed entirely on an outpatient basis. Despite multiple adjustments to antipsychotic medications (risperidone, then haloperidol, then aripiprazole), the patient showed only a partial response to treatment, leading to their classification as treatment-resistant. THE PRIMARY DIAGNOSES, INTERVENTIONS, AND OUTCOMES: Due to the lack of adequate response, the medical team decided to prescribe clozapine. However, at a dose of 350 mg, clozapine triggered compulsive checking and washing behaviors. Consequently, the team initiated treatment with a third-generation antipsychotic, cariprazine, at a dose of 6 mg, combined with sertraline at 100 mg while gradually reducing clozapine. Unexpectedly, there was a significant improvement in both psychotic symptoms and OCS.

conclusionThe combination of cariprazine, as a D3 partial agonist, with clozapine may be an effective approach for managing challenging cases of treatment-resistant schizophrenia associated with de novo OCS.

Indexed as

Antipsychotic AgentsClozapineObsessive-Compulsive DisorderPiperazinesSchizophrenia, Treatment-ResistantDrug Therapy, CombinationHumansSchizophreniaSertralineAntipsychotic AgentscariprazineClozapinePiperazinesSertralineCariprazineClozapineCompulsive behaviorsObsessive–compulsive symptoms (OCS)Psychotic symptomsSertralineTreatment-resistant schizophrenia

Identifiers

PMID41787366
PMCPMC12964601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.